Association of blood group A with early-onset ovarian hyperstimulation syndrome

Transfusion Clinique et Biologique

Volumn 15, Issue 6, 2008, Pages 395-401

  Binder, H ^a   Flegel, W A ^b   Emran, J ^a   Muller A ^a   Dittrich, R ^a   Beckmann, M W ^a   Zingsem, J ^c   Eckstein, R ^c   Ringwald, J ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

ABO; Blood group; Case control study; Female infertility; Ovarian hyperstimulation; Von Willebrand factor

Indexed keywords

ADULT; ARTICLE; BLOOD GROUP A; BLOOD GROUP ABO SYSTEM; BLOOD GROUP O; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FERTILIZATION IN VITRO; HUMAN; JUGULAR VEIN; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; PREGNANCY RATE; SUBCLAVIAN VEIN; SYMPTOMATOLOGY; VEIN THROMBOSIS;

ABO BLOOD-GROUP SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FERTILIZATION IN VITRO; GERMANY; HUMANS; ODDS RATIO; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 56949099322     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2008.06.002     Document Type: Article

References (31)

1. Ben-Chetrit A., Eldar-Geva T., Gal M., Huerta M., Mimon T., Algur N., et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 16 (2001) 1880-1884
2. Bellver J., Muñoz E.A., Ballesteros A., Soares S.R., Bosch E., Simón C., et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 18 (2003) 2283-2288
3. Kaiser U.B. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 349 (2003) 7297-7332
4. Binder H., Dittrich R., Einhaus F., Krieg J., Müller A., Strauss R., et al. Update on ovarian hyperstimulation syndrome: part 1 - incidence and pathogenesis. Int J Fertil Womens Med 52 (2007) 251-255
5. Rizk B. Ovarian hyperstimulation syndrome. Epidemiology, pathophysiology, prevention and management (2006), Cambridge University Press, Cambridge p. 1-129
6. Schenker J.G., and Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 30 (1978) 255-268
7. Mathur R., Evbuomwan I., and Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Curr Obstet Gynaecol 15 (2005) 132-138
8. Delvigne A., and Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 9 (2003) 77-96
9. Mathur R.S., Akande A.V., Keay S.D., Hunt L.P., and Jenkins J.M. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 73 (2000) 901-907
10. Papanikolaou E.G., Tournaye H., Verpoest W., Camus M., Vernaeve V., Van Steirteghem A., et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 20 (2005) 636-641
11. Delbaere A., Smits G., Vassart G., and Costagliola S. Genetic predictors of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Nat Clin Pract Endocrinol Metab 2 (2006) 590-591
12. Binder H., Dittrich R., Hager I., Müller A., Oeser S., Beckmann M.W., et al. Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. Reproduction 135 (2008) 107-116
13. Mathur R., Evbuomwan I., and Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Curr Obstet Gynaecol 12 (2002) 111-116
14. Todorow S., Schricker S.T., Siebzehnruebl E.R., Neidhardt B., Wildt L., and Lang N. Von Willebrand factor: an endothelial marker to monitor in-vitro fertilization patients with ovarian hyperstimulation syndrome. Hum Reprod 8 (1993) 2039-2046
15. Chan WS, Dixon ME. The "ART" of thromboembolism: A review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008;121(6):713-26.
16. Garratty G. Blood group antigens as tumor markers, parasitic/bacterial/viral receptors, and their association with immunologically important proteins. Immunol Invest 24 (1995) 213-232
17. Nefzger M.D., Hrubec Z., and Chalmers T.C. Venous thromboembolism and blood-group. Lancet 1 (1969) 887
18. Allan T.M. Venous thromboembolism and blood-group. Lancet 1 (1970) 303
19. O'Donnell J., and Laffan M.A. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 11 (2001) 343-351
20. Jenkins P.V., and O'Donnell J.S. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion 46 (2006) 1836-1844
21. Solish G.I., and Gershowitz H. Distribution of ABO blood types among fertile and infertile women. Am J Hum Genet 21 (1969) 23-35
22. Wagner F.F., Kasulke D., Kerowgan M., and Flegel W.A. Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in south-western Germany. Infusionsther Transfusionsmed 22 (1995) 285-290
23. Schaap T., Shemer R., Palti Z., and Sharon R. ABO incompatibility and reproductive failure. I. Prenatal selection. Am J Hum Genet 36 (1984) 143-151
24. Omu A.E., Al-Mutawa M., and Al-Qattan F. ABO blood group and expression of antisperm antibodies in infertile couples in Kuwait. Gynecol Obstet Invest 45 (1998) 49-53
25. Ogawa S., Minakami H., Araki S., Ohno T., Motoyama M., Shibahara H., et al. A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome. J Assist Reprod Genet 18 (2001) 114-119
26. Davies J.A., Collins P.W., Hathaway L.S., and Bowen D.J. The effect of von Willebrand factor Y/C1584 on in vivo protein level and function, and interaction with ABO blood group. Blood 109 (2007) 2840-2846
27. Hulstein J.J., van Runnard, Heimel P.J., Franx A., Lenting P.J., Bruinse H.W., et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 4 (2006) 2569-2575
28. Tousoulis D., Antoniades C., Bosinakou E., Kotsopoulou M., Tsoufis C., Marinou K., et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. Int J Cardiol 115 (2007) 203-207
29. Solheim B.G., and Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 35 (2006) 83-90
30. Cepkova M., Brady S., Sapru A., Matthay M.A., and Church G. Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury. Crit Care 10 (2006) R126
31. Binder H., Flegel W., Emran S., Müller A., Cupisti S., Beckmann M.W., et al. Blood group A: an overseen risk factor for early-onset ovarian hyperstimulation syndrome?. Reprod Biomed Online 17 (2008) 185-189